Stockreport

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics Limited - American Depositary Shares  (KZIA) 
US:NASDAQ Investor Relations: kaziatherapeutics.com
PDF SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combina [Read more]